Fate Therapeutics sets up $100 million at-the-market stock sale program with Leerink Partners

Fate Therapeutics entered a Sales Agreement with Leerink Partners for an at-the-market program allowing it to sell up to $100 million of common stock at its discretion, and terminated its earlier $100 million program with Jefferies. The company has already sold 2,801,602 shares for $8.0 million under the Jefferies program. The new program could add shares outstanding and dilute existing shareholders if the company chooses to sell.

Key points

• Leerink Partners may sell up to $100,000,000 of common stock; the company pays a commission of up to 3.0% of gross proceeds.
• The Jefferies program was terminated on November 5, 2026, with no termination penalties, after sales of 2,801,602 shares for $8.0 million.
• The existing Form S-3 expires November 27, 2026; the company plans to file a new registration statement, and may sell under the existing one until the earlier of the new registration's effectiveness and May 26, 2027.

The filing

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.